Dr. Andrew Geall has over 20 years of experience developing drug delivery systems as a pioneer in mRNA vaccines and nucleic acid delivery. He currently serves as the chief development officer at Replicate Bioscience, which he cofounded. Prior to Replicate, Andrew was chief scientific officer at Precision NanoSystems Inc. He has also served as vice president of formulations, analytics and chemistry at Avidity Biosciences, RNA Vaccine Platform Leader at Novartis Vaccines, and Senior Fellow at Novartis Pharmaceuticals AG.
Andrew holds a pharmacy degree from the University of Bath in the United Kingdom and completed pre-registration training in the aseptic dispensing unit at St Helens and Knowsley Trust Hospitals. He obtained a Ph.D. at the University of Bath in non-viral gene delivery.